Detection of novel biomarkers for mesothelioma and development of novel therapeutic agents

间皮瘤新型生物标志物的检测和新型治疗药物的开发

• 批准号: 2755531
• 金额: --
• 依托单位: University of Surrey
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2755531
• 关键词: Detection; novel; biomarkers; mesothelioma; development

Human malignant pleural mesothelioma (MPM) is an aggressive (fatal) lung cancer which is always associated with asbestos exposure. Typically symptoms do not appear until 20-40 years after the original exposure, with life expectancy then 12-18 months. Given the widespread use of asbestos during the 20th century and this long latency period, it is no surprise that cases of MPM continue to rise. Therefore there is an urgent need to develop novel therapeutic approaches for the treatemnt of MPM.Currently, early diagnosis is a significant problem as it is only possible via biopsy and this normally only takes place once symptoms appear. The project proposes to investigate novel biomarkers for the early diagnosis of mesothelioma, utilising the resources at the Ion Beam Centre located at the University of Surrey and will look at breath analysis and fingerprint analysis as well as biomarkers from tissues and tumours.

人类恶性胸膜间皮瘤（MPM）是一种侵袭性（致命性）肺癌，通常与石棉暴露有关。通常情况下，症状不会出现，直到20-40年后，原来的接触，与预期寿命，然后12-18个月。鉴于20世纪石棉的广泛使用和如此长的潜伏期，MPM病例继续增加也就不足为奇了。因此，迫切需要开发新的治疗方法来预防MPM。目前，早期诊断是一个重要的问题，因为它只能通过活检，这通常只发生在症状出现时。该项目提议利用萨里大学离子束中心的资源，研究用于间皮瘤早期诊断的新型生物标志物，并将研究呼吸分析和指纹分析以及组织和肿瘤的生物标志物。